• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

良性多发性硬化症患者的长期分析:对残疾病程的新认识。

Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.

机构信息

Department of Neurology, Nancy University Hospital, Hôpital Central, service de neurologie, 29 avenue du Maréchal de Lattre de Tassigny, 54035, Nancy, France.

Université de Lorraine, EA 4360 APEMAC, 54500, Nancy, France.

出版信息

J Neurol. 2021 Oct;268(10):3817-3825. doi: 10.1007/s00415-021-10501-0. Epub 2021 Mar 31.

DOI:10.1007/s00415-021-10501-0
PMID:33791847
Abstract

OBJECTIVE

To describe the course of disability in patients with benign multiple sclerosis-i.e., with an expanded disability status scale score < 3 10 years after disease onset-for up to 30 years after disease onset. We evaluated the proportion of patients remaining in the benign state on the long term and the factor associated with this favorable outcome and determined the pattern of disability course after the loss of the benign status.

METHODS

Patients were selected from the ReLSEP, a French population-based registry. We studied the probability (Kaplan-Meier method) and predictors (multivariate Cox model) of remaining < 3 after year 10, and the course of disability after score 3 according to the duration of the benign phase in patients with ≥ 30 years of follow-up (graphs of the course of the mean expanded disability status scale scores in subgroups of patients).

RESULTS

2295/3440 patients had benign multiple sclerosis (66.7%). The probability of remaining benign at year 30 was 0.26 (95% CI 0.26-0.32). A young age at disease onset and a good recovery after the first relapse were associated with remaining benign. Graphs illustrate that those who lost their benign status between years 10 and 30 follow a two-stage course. Beyond score 3, disability accumulation is similar in all but lower disability scores at advanced age are associated with longer benign periods.

CONCLUSION

The longer a patient remains in the benign state, the lower the final EDSS at advanced age.

摘要

目的

描述发病 10 年后残疾状况扩展量表评分(EDSS)<3 的良性多发性硬化症患者的病程,最长可达发病后 30 年。我们评估了长期处于良性状态的患者比例、与这种有利结局相关的因素,并确定了失去良性状态后残疾进程的模式。

方法

患者选自法国基于人群的 ReLSEP 登记处。我们研究了发病 10 年后评分仍<3 的概率(Kaplan-Meier 法)及其预测因素(多变量 Cox 模型),以及在随访时间≥30 年的评分≥3 的患者中,良性期持续时间对残疾进程的影响(根据患者亚组的平均 EDSS 评分曲线图)。

结果

2295/3440 例患者为良性多发性硬化症(66.7%)。发病 30 年时仍保持良性的概率为 0.26(95%CI 0.26-0.32)。发病年龄较小和首次复发后恢复良好与保持良性相关。曲线图表明,在发病 10 年至 30 年之间失去良性状态的患者呈两阶段病程。评分>3 后,残疾累积在所有患者中相似,但在高龄时的较低残疾评分与较长的良性期相关。

结论

患者处于良性状态的时间越长,高龄时的最终 EDSS 越低。

相似文献

1
Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course.良性多发性硬化症患者的长期分析:对残疾病程的新认识。
J Neurol. 2021 Oct;268(10):3817-3825. doi: 10.1007/s00415-021-10501-0. Epub 2021 Mar 31.
2
Longitudinal follow-up of "benign" multiple sclerosis at 20 years.“良性”多发性硬化症20年的纵向随访
Neurology. 2007 Feb 13;68(7):496-500. doi: 10.1212/01.wnl.0000253185.03943.66.
3
Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.良性多发性硬化症?临床病程、长期随访及预后因素评估
J Neurol Neurosurg Psychiatry. 1999 Aug;67(2):148-52. doi: 10.1136/jnnp.67.2.148.
4
Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.与良性多发性硬化症相关的因素及其长期预后:一项全国性队列研究。
J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):761-767. doi: 10.1136/jnnp-2018-319913. Epub 2019 Mar 1.
5
Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study.中国多发性硬化症患者长期残疾的预测:一项前瞻性队列研究。
Mult Scler Relat Disord. 2020 Nov;46:102461. doi: 10.1016/j.msard.2020.102461. Epub 2020 Aug 22.
6
Natural history of benign multiple sclerosis: Clinical and HLA correlates in a Western Australian cohort.良性多发性硬化的自然史:西澳大利亚队列的临床和 HLA 相关性。
J Neurol Sci. 2018 May 15;388:12-18. doi: 10.1016/j.jns.2018.02.036. Epub 2018 Feb 22.
7
Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?突尼斯多发性硬化症的临床特征与残疾进展:我们真的患有更具侵袭性的病程吗?
J Neurol Sci. 2014 Aug 15;343(1-2):110-4. doi: 10.1016/j.jns.2014.05.049. Epub 2014 Jun 2.
8
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.儿童发病多发性硬化症患者延迟治疗对残疾的长期影响:一项前瞻性丹麦队列研究。
Mult Scler Relat Disord. 2020 May;40:101956. doi: 10.1016/j.msard.2020.101956. Epub 2020 Jan 17.
9
Evidence for a two-stage disability progression in multiple sclerosis.多发性硬化症中存在两阶段残疾进展的证据。
Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.
10
Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension.多发性硬化症中的残疾与预后:对行走能力及残疾抚恤金授予至关重要的人口统计学和临床变量
Mult Scler. 2001 Feb;7(1):59-65. doi: 10.1177/135245850100700110.

引用本文的文献

1
Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症恶性进展的预测因素及治疗挑战
Heliyon. 2024 Feb 17;10(4):e26658. doi: 10.1016/j.heliyon.2024.e26658. eCollection 2024 Feb 29.
2
Multiple sclerosis: time for early treatment with high-efficacy drugs.多发性硬化症:是时候用高效药物进行早期治疗了。
J Neurol. 2024 Jan;271(1):105-115. doi: 10.1007/s00415-023-11969-8. Epub 2023 Oct 18.
3
Absence of Oligoclonal Bands in Multiple Sclerosis: A Call for Differential Diagnosis.

本文引用的文献

1
Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study.与良性多发性硬化症相关的因素及其长期预后:一项全国性队列研究。
J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):761-767. doi: 10.1136/jnnp-2018-319913. Epub 2019 Mar 1.
2
Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.多发性硬化症发病年龄较大是预后不良的独立因素:一项基于人群的队列研究。
Neuroepidemiology. 2017;48(3-4):179-187. doi: 10.1159/000479516. Epub 2017 Aug 10.
3
Defining the clinical course of multiple sclerosis: the 2013 revisions.
多发性硬化症中寡克隆带缺失:呼吁进行鉴别诊断。
J Clin Med. 2023 Jul 13;12(14):4656. doi: 10.3390/jcm12144656.
4
Movement Disorders in Demyelinating Disorders: How Important Is This Historical Link Today?脱髓鞘疾病中的运动障碍:如今这种历史关联有多重要?
Ann Indian Acad Neurol. 2022 Sep-Oct;25(5):790-791. doi: 10.4103/aian.aian_406_22. Epub 2022 Jul 26.
多发性硬化症临床病程的定义:2013年修订版
Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
4
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.对多发性硬化症患者的扩展残疾状况量表(EDSS)和多发性硬化症功能综合评定量表(MSFC)进行系统文献回顾和有效性评估。
BMC Neurol. 2014 Mar 25;14:58. doi: 10.1186/1471-2377-14-58.
5
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.英国多发性硬化症风险分担计划:一个新的自然史数据集和一个改进的马尔可夫模型。
BMJ Open. 2014 Jan 17;4(1):e004073. doi: 10.1136/bmjopen-2013-004073.
6
Age and disability accumulation in multiple sclerosis.多发性硬化症中的年龄和残疾累积。
Neurology. 2011 Sep 27;77(13):1246-52. doi: 10.1212/WNL.0b013e318230a17d. Epub 2011 Sep 14.
7
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs.多发性硬化症临床试验面临的挑战:疾病修正药物时代的疗效评估指标。
Curr Opin Neurol. 2011 Jun;24(3):255-61. doi: 10.1097/WCO.0b013e3283460542.
8
New perspectives in the natural history of multiple sclerosis.多发性硬化症自然史的新视角。
Neurology. 2010 Jun 15;74(24):2004-15. doi: 10.1212/WNL.0b013e3181e3973f.
9
Evidence for a two-stage disability progression in multiple sclerosis.多发性硬化症中存在两阶段残疾进展的证据。
Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.
10
Natural history of multiple sclerosis in a population-based cohort.基于人群队列的多发性硬化症自然史
Eur J Neurol. 2008 Sep;15(9):916-21. doi: 10.1111/j.1468-1331.2008.02241.x. Epub 2008 Jul 15.